Abstract
In this issue of Radiology, Saeed et al (1) describe the intramyocardial administration of VM202, a newly constructed plasmid human hepatocyte growth factor, in a pig model of myocardial infarction. Histopathologic findings were used to characterize and quantify neovascularization, while magnetic resonance (MR) imaging findings were used to quantify left ventricular function, perfusion, and infarct size. Compared with control animals, VM202-treated animals demonstrated an increase in number of capillaries, improved perfusion and left ventricular ejection fraction, and reduced infarct size.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
